1. Home
  2. RGNX vs BAND Comparison

RGNX vs BAND Comparison

Compare RGNX & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGNX
  • BAND
  • Stock Information
  • Founded
  • RGNX 2008
  • BAND 2000
  • Country
  • RGNX United States
  • BAND United States
  • Employees
  • RGNX N/A
  • BAND N/A
  • Industry
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • BAND Computer Software: Prepackaged Software
  • Sector
  • RGNX Health Care
  • BAND Technology
  • Exchange
  • RGNX Nasdaq
  • BAND Nasdaq
  • Market Cap
  • RGNX 451.1M
  • BAND 473.2M
  • IPO Year
  • RGNX 2015
  • BAND 2017
  • Fundamental
  • Price
  • RGNX $9.03
  • BAND $18.29
  • Analyst Decision
  • RGNX Strong Buy
  • BAND Buy
  • Analyst Count
  • RGNX 8
  • BAND 6
  • Target Price
  • RGNX $28.50
  • BAND $20.80
  • AVG Volume (30 Days)
  • RGNX 502.6K
  • BAND 262.3K
  • Earning Date
  • RGNX 11-05-2025
  • BAND 10-30-2025
  • Dividend Yield
  • RGNX N/A
  • BAND N/A
  • EPS Growth
  • RGNX N/A
  • BAND N/A
  • EPS
  • RGNX N/A
  • BAND N/A
  • Revenue
  • RGNX $155,782,000.00
  • BAND $758,106,000.00
  • Revenue This Year
  • RGNX $203.27
  • BAND $2.48
  • Revenue Next Year
  • RGNX $0.58
  • BAND $13.24
  • P/E Ratio
  • RGNX N/A
  • BAND N/A
  • Revenue Growth
  • RGNX 74.95
  • BAND 14.51
  • 52 Week Low
  • RGNX $5.04
  • BAND $11.33
  • 52 Week High
  • RGNX $13.48
  • BAND $23.00
  • Technical
  • Relative Strength Index (RSI)
  • RGNX 49.37
  • BAND 74.28
  • Support Level
  • RGNX $8.82
  • BAND $14.97
  • Resistance Level
  • RGNX $10.08
  • BAND $17.09
  • Average True Range (ATR)
  • RGNX 0.54
  • BAND 0.73
  • MACD
  • RGNX -0.05
  • BAND 0.26
  • Stochastic Oscillator
  • RGNX 25.27
  • BAND 91.46

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

About BAND Bandwidth Inc.

Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.

Share on Social Networks: